Vehicle Recompete: Idc 75N91023D00005

This contract is an indefinite delivery indefinite quantity (IDIQ) agreement for the procurement of nilotinib tablets to support the U.S. Department of Health and Human Services, specifically the National Institutes of Health (NIH) National Cancer Institute (NCI). The ordering period for this vehicle extends until March 26, 2027, with a total contract ceiling of $6.34 million. It is designated as a total small business set-aside, ensuring that the contract opportunities are exclusively reserved for small businesses. The contract is classified as a recompete-likely, indicating that it is a renewal of a previous contract with moderate confidence. Currently, there are no active task orders under this contract valued at zero, but one notable task order, Delivery Order 4, involved the procurement of 36 blisters of 200 mg nilotinib capsules, valued at approximately $219,850 and awarded to Regimed Medical. The contract is managed through the NIH NCI contracting office and falls under NAICS code 325412, relating to pharmaceutical product manufacturing. This contract ensures a reliable supply of nilotinib tablets to support oncology-related research and treatments conducted or supported by the NCI.